End-ischemic hypothermic oxygenated machine perfusion (HOPE) of human donor livers mitigates ischemia-reperfusion injury, resulting in a reduction of post-reperfusion syndrome, early allograft dysfunction and biliary complications, when compared with static cold storage. According to IDEAL-D (Idea, Development, Exploration, Assessment, Long term study-Framework for Devices), with several published randomized controlled trials on short-to-medium term outcomes, scientific evidence for HOPE has currently reached stage 3. Assessment of long-term outcomes after HOPE preservation based on real-world data (i.e., IDEAL-D stage 4) is currently still lacking. Therefore, we aim to conduct an international, multi-center, retrospective, observational cohort study to assess long-term outcomes after transplantation of donor livers preserved by hypothermic oxygenated machine perfusion (HOPE).
Study Type
OBSERVATIONAL
Enrollment
1,202
After static cold storage, all grafts included in this study are subjected to \>1 hour of hypothermic oxygenated machine perfusion at 4-12°C with an acellular perfusion solution.
University Medical Center Groningen
Groningen, Netherlands
University Hospital Zürich
Zurich, Switzerland
Death-censored graft survival, assessed by survival analysis methods
Defined as time from liver transplantation until re-transplantation or death due to graft dysfunction
Time frame: Up to 5-years
Overall graft survival
Defined as time from liver transplantation until re-transplantation or all-cause death
Time frame: Up to 5-years
Overall patient survival
Defined as time from liver transplantation until all-cause death
Time frame: Up to 5-years
Arterial and biliary complication-free survival (ABCFS)
Defined as time from liver transplantation until occurrence of an arterial or biliary complication of Dindo-Clavien grade ≥3, dated at the time of interventional, endoscopic, or surgical treatment required to correct it (Savier E, De Rycke Y, Lim C, et al. Novel Composite Endpoint for Assessing Outcomes in Liver Transplantation: Arterial and Biliary Complication-Free Survival. Liver Transpl. 2022;28(1):75-87. doi:10.1002/lt.26269)
Time frame: Up to 5-years
Incidence of biliary complications
Defined as a composite of: * Non-anastomotic biliary strictures: any irregularity or narrowing of the lumen of the intrahepatic or extrahepatic donor bile ducts, excluding the biliary anastomosis, diagnosed with the use of cholangiography in combination with clinical symptoms (e.g., jaundice or cholangitis) or an elevation of cholestatic laboratory variables, in the presence of a patent hepatic artery * Anastomotic biliary strictures: strictures occurring at the anastomosis of donor choledochal duct and recipient choledochal duct or jejunal Roux-limb * Biliary leakage: fluid with an elevated (\>3x serum) bilirubin level in the abdominal drain or intra-abdominal fluid on or after post-operative day 3 or the need for radiological intervention (i.e. interventional drainage) owing to biliary collections or re-laparotomy due to biliary peritonitis
Time frame: Up to 5-years
Incidence of vascular complications
Defined as a composite of: * Hepatic arterial thrombosis: radiologically or surgically proven thrombosis of the hepatic artery * Portal vein thrombosis: radiologically or surgically proven thrombosis of the portal vein * Venous outflow tract obstruction: radiologically or surgically proven thrombosis of the main hepatic veins or the inferior vena cava
Time frame: Up to 5-years
Incidence of acute cellular rejection
Defined as biopsy proven Banff grade 2 or 3 rejection (Demetris AJ, Bellamy C, Hübscher SG, et al. 2016 Comprehensive Update of the Banff Working Group on Liver Allograft Pathology: Introduction of Antibody-Mediated Rejection. Am J Transplant. 2016;16(10):2816-2835. doi:10.1111/ajt.13909)
Time frame: Up to 5-years
Incidence of chronic rejection
Defined as histopathological evidence of immunologic injury with irreversible damage to the bile ducts, arteries, and veins (Demetris A, Adams D, Bellamy C, et al. Update of the International Banff Schema for Liver Allograft Rejection: working recommendations for the histopathologic staging and reporting of chronic rejection. An International Panel. Hepatology. 2000;31(3):792-799. doi:10.1002/hep.510310337)
Time frame: Up to 5-years
Incidence of re-transplantation
Defined as proportion of patients who underwent liver re-transplantation for any cause
Time frame: Up to 5-years
Incidence of recurrence of primary disease (including recurrence of malignancies)
Defined as histological or radiologically confirmed recurrence
Time frame: Up to 5-years
Incidence of new-onset chronic kidney disease
Defined as renal impairment (kidney morphology, pathology, imaging, blood or urine composition abnormalities) persisting for \>3 months with or without eGFR decrease, and/or eGFR \<60 for \>3 months with or without renal impairment (Levey AS, Eckardt K-U, Tsukamoto Y, et al. Definition and Classification of Chronic Kidney Disease: A Position Statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2005 Jun;67(6):2089-100. doi: 10.1111/j.1523-1755.2005.00365.x)
Time frame: Up to 5-years
Incidence of new-onset diabetes after transplantation
Defined as symptoms of diabetes plus casual plasma glucose levels ≥200 mg/dL (11.1 mmol/L) or fasting plasma glucose ≥126 mg/dL (7.0 mmol/L) or 2 hours plasma glucose ≥200 mg/dL (11.1 mmol/L during an oral glucose tolerance testing (Davidson J, Wilkinson A, Dantal J, et al. New-onset diabetes after transplantation: 2003 International consensus guidelines. Proceedings of an international expert panel meeting. Barcelona, Spain, 19 February 2003. Transplantation. 2003;75(10 Suppl):SS3-24. doi:10.1097/01.TP.0000069952.49242.3E)
Time frame: Up to 5-years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.